Patents by Inventor Mark P. Keller

Mark P. Keller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alpha/beta-polypeptide analogs of glucagon-like peptide 1
    Patent number: 10723779
    Abstract: Described herein are peptide analogs of glucagon-like peptide 1 (GLP-1) that retain agonist activity, but are more resistant to proteolytic degradation than native GLP-1. In the analogs, at least one ?-amino acid found in the native GLP-1 is replaced with a ?-amino acid residue, which may or may not be cyclically constrained. Pharmaceutical compositions containing the analogs are described, as are methods to treat diabetes, and methods to make proteolytically resistant GLP-1 analogs.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: July 28, 2020
    Assignees: Wisconsin Alumni Research Foundation, President and Fellows of Harvard College
    Inventors: Samuel H. Gellman, Lisa M. Johnson, Alan Attie, Mark P. Keller, Alan Saghatelian
  • ALPHA/BETA-POLYPEPTIDE ANALOGS OF GLUCAGON-LIKE PEPTIDE 1
    Publication number: 20170320928
    Abstract: Described herein are peptide analogs of glucagon-like peptide 1 (GLP-1) that retain agonist activity, but are more resistant to proteolytic degradation than native GLP-1. In the analogs, at least one ?-amino acid found in the native GLP-1 is replaced with a ?-amino acid residue, which may or may not be cyclically constrained. Pharmaceutical compositions containing the analogs are described, as are methods to treat diabetes, and methods to make proteolytically resistant GLP-1 analogs.
    Type: Application
    Filed: July 13, 2017
    Publication date: November 9, 2017
    Inventors: Samuel H. Gellman, Lisa M. Johnson, Alan Attie, Mark P. Keller, Alan Saghatelian
  • Alpha/beta-polypeptide analogs of glucagon-like peptide-1
    Patent number: 9738697
    Abstract: Described herein are peptide analogs of glucagon-like peptide 1 (GLP-1) that retain agonist activity, but are more resistant to proteolytic degradation than native GLP-1. In the analogs, at least one ?-amino acid found in the native GLP-1 is replaced with a ?-amino acid residue, which may or may not be cyclically constrained. Pharmaceutical compositions containing the analogs are described, as are methods to treat diabetes, and methods to make proteolytically resistant GLP-1 analogs.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: August 22, 2017
    Assignees: Wisconsin Alumni Research Foundation, President and Fellows Of Harvard College
    Inventors: Samuel H. Gellman, Lisa M. Johnson, Alan Attie, Mark P. Keller, Alan Saghatelian
  • ALPHA/BETA-POLYPEPTIDE ANALOGS OF GLUCAGON-LIKE PEPTIDE 1
    Publication number: 20140378375
    Abstract: Described herein are peptide analogs of glucagon-like peptide 1 (GLP-1) that retain agonist activity, but are more resistant to proteolytic degradation than native GLP-1. In the analogs, at least one ?-amino acid found in the native GLP-1 is replaced with a ?-amino acid residue, which may or may not be cyclically constrained. Pharmaceutical compositions containing the analogs are described, as are methods to treat diabetes, and methods to make proteolytically resistant GLP-1 analogs.
    Type: Application
    Filed: June 23, 2014
    Publication date: December 25, 2014
    Inventors: Samuel H. Gellman, Lisa M. Johnson, Alan Attie, Mark P. Keller, Alan Saghatelian